IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors• New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, Illinois. One of the posters will share insights, using non-clinical models, related to IO Biotech’s lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced melanoma. The se
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech (NASDAQ:IOBT) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications [Yahoo! Finance]Yahoo! Finance
- IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsGlobeNewswire
- IO Biotech (NASDAQ:IOBT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IOBT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
- IO Biotech Announces Participation in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
IOBT
Sec Filings
- 12/19/25 - Form 8-K
- 11/21/25 - Form 8-K
- 11/18/25 - Form 8-K
- IOBT's page on the SEC website